Navigating Global Clinical Trials with Comprehensive Genomic Profiling Discover how IQVIA Laboratories is transforming precision oncology and global clinical trials through advanced genomic profiling. On October 7, 2025, leading experts from IQVIA Laboratories joined GenomeWeb for a virtual Lunch and Learn, spotlighting the future of clinical trials powered by the Illumina TruSight Oncology 500 (TSO500) next-generation sequencing assay. Attendees from across the biopharma industry learned how IQVIA’s global network is driving innovation in biomarker discovery and companion diagnostics (CDx), supporting trials in Europe, the US, and China.
Key Takeaways
- Global Reach & Speed: IQVIA Laboratories is the first global CRO to offer the TSO500 family of assays, enabling rapid, reliable results for patient enrollment worldwide—typically within 10 business days. Comprehensive Profiling: The TSO500 assay covers over 500 cancer-related genes, supporting both solid tumor and liquid biopsy profiling. Its versatility makes it ideal for biomarker development and CDx testing
- Rigorous Validation: IQVIA’s CAP/CLIA-compliant validation ensures accuracy, precision, and reproducibility across sites, with harmonized SOPs and instrumentation to eliminate site-to-site variability. Custom Reporting: Patient-specific reports are reviewed by board-certified molecular pathologists, delivering actionable insights and clinical trial matches to sites quickly and consistently.
- Global Expertise: With 19 laboratories on five continents and over 25 years of genomics experience, IQVIA Laboratories offers seamless support for biopharma partners, backed by deep regulatory knowledge and bioinformatics expertise. Why Choose IQVIA Laboratories? Seamless Global Operations: Centralized development and harmonized protocols ensure consistency and reliability, no matter where your trial is conducted.
- Regulatory Strength: IQVIA’s team helps sponsors navigate complex frameworks like IVDR in Europe and local requirements in China. Commitment to Excellence: Every sample is treated as if a life depends on it—anchoring IQVIA’s mission to improve patient outcomes through scientific rigor and innovation. Ready to advance your clinical trial with comprehensive genomic profiling? Connect with IQVIA Laboratories today to learn how our expertise can accelerate your precision oncology research.
Download Document
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
